New Acrivon (NASDAQ: ACRV) preclinical data back combo strategy

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. furnished a corporate presentation on its website, providing an update on its business and research programs. The presentation includes new syngeneic mouse model data showing continued strong synergy between its clinical candidates ACR-368 and ACR-2316 and immune checkpoint inhibitors. After multiple rounds of tumor implantation over almost one year, the models showed complete tumor regression and evidence of immune memory, and the company further analyzed which immune cell types drive this effect. These results support the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting. The company also updated its pipeline overview to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial and expanded information on its Generative Phosphoproteomics AP3 platform. The presentation is attached as Exhibit 99.1.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001781174false00017811742025-09-052025-09-05

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 05, 2025

Acrivon Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41551	82-5125532
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
480 Arsenal Way Suite 100
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 207-8979

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ACRV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 5, 2025, the Company posted to the “Investors & Media” section of the Company’s website at ir.acrivon.com, a corporate presentation providing an update on the Company’s business (the “Corporate Presentation”). This updated Corporate Presentation includes additional follow up syngeneic mouse model data where we observed continued strong synergy between each of our clinical candidates, ACR-368 and ACR-2316, with immune check point inhibitors. After multiple rounds of tumor implantations over almost one year, there is continued complete tumor regression and immune memory and we have further dissected which types of immune cells are responsible for the immune memory. This provides support for the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting.

In addition, we have updated the pipeline overview slide to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial, which had been previously referenced, as well as updated information regarding our Generative Phosphoproteomics AP3 platform highlighting the capabilities of the platform in the generation of actionable, differentiated pathway-based insights for novel drug design and development.

A Copy of the Corporate Presentation is attached hereto as Exhibit 99.1, and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Acrivon Therapeutics, Inc., Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Acrivon Therapeutics, Inc.
Date:	September 5, 2025	By:	/s/ Peter Blume-Jensen
			Name: Peter Blume-Jensen, M.D., Ph.D. Title: President and Chief Executive Officer

FAQ

What did Acrivon Therapeutics (ACRV) disclose in this 8-K?

Acrivon Therapeutics reported that it posted an updated corporate presentation on its website, attached as Exhibit 99.1, providing an update on its business, pipeline and research data.

What new preclinical data did Acrivon (ACRV) highlight?

The company highlighted additional syngeneic mouse model data showing continued strong synergy between its clinical candidates ACR-368 and ACR-2316 and immune checkpoint inhibitors, with complete tumor regression and immune memory after repeated tumor implantations.

How do the new data support Acrivon’s development strategy?

The preclinical results provide support for the rationale for potential combinations of ACR-368 and ACR-2316 with anti-PD(L)1 agents in the front line setting, based on observed synergy and immune memory in the mouse models.

What changes did Acrivon make to its pipeline overview in the presentation?

The pipeline overview slide was updated to include the all-comer ACR-368 + ULDG ARM 3 of the ongoing ACR-368-201 trial, which had been previously referenced.

What is Acrivon’s Generative Phosphoproteomics AP3 platform and how was it updated?

The presentation updates information on the Generative Phosphoproteomics AP3 platform, highlighting its capabilities to generate actionable, differentiated pathway-based insights for novel drug design and development.

Is the Acrivon corporate presentation considered filed for liability purposes?

The information in Item 7.01, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated by reference into other Securities Act or Exchange Act filings.